Unicycive Therapeutics, Inc.
UNCYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 27, 2026 | H.C. Wainwright | Swayampakula Ramakanth | $22.00(+212%) | $7.06 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 29, 2026 |
| Benchmark | maintain | Speculative Buy | Aug 20, 2026 |
| B. Riley Securities | maintain | Buy | Aug 13, 2026 |
| Guggenheim | maintain | Buy | Aug 13, 2026 |
| Noble Capital Markets | maintain | Outperform | Jul 1, 2026 |
| Benchmark | maintain | Speculative Buy | Jul 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 30, 2026 |
| B. Riley Securities | maintain | Buy | Jun 30, 2026 |
| Benchmark | maintain | Speculative Buy | Jun 2, 2026 |
| Guggenheim | maintain | Buy | May 13, 2026 |
| Benchmark | maintain | Speculative Buy | Apr 6, 2026 |
| Guggenheim | maintain | Buy | Apr 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 29, 2025 |
| Benchmark | maintain | Speculative Buy | Sep 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 8, 2025 |
| Benchmark | maintain | Speculative Buy | Nov 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 9, 2024 |
| Benchmark | maintain | Speculative Buy | Sep 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.33| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.06 | $-0.47 | — | $22.2M |
| May 12, 2026 | $-0.54 | $-0.55 | — | $11.1M |
| Mar 30, 2026 | $-0.82 | $-0.46 | — | $517.0K |
| Nov 12, 2025 | $-0.33 | $-0.59 | — | $2.4M |
| Aug 14, 2025 | $-0.52 | $-0.70 | — | — |
| May 14, 2025 | $-0.50 | $-0.67 | — | — |
| Mar 27, 2025 | $-2.76 | $-0.13 | — | $10.0M |
| Nov 13, 2024 | $-0.50 | $-0.86 | — | $10.0M |
News
MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.
NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, Calif…
Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options. A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manu…
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. …
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
Unicycive Therapeutics is rated Buy, with a risk-adjusted fair value of $6.97 per share, nearly 95% upside from current prices. UNCY's lead drug, OLC, targets hyperphosphatemia in CKD dialysis patients, with a PDUFA date set for March 25, 2027, after resolving manufacturing issues. Despite $61.4M in cash, a likely capital raise for commercialization could possibly as much as double share count, heavily diluting shareholders.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. …
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us.
A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter. NEW YORK, Oct. 29, 2026 /PRNewswire/ -- SueWallSt notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action has been filed on behalf of shareholders who purchase…
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026
Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc.
A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection. NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ:…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. …
New York, New York--(Newsfile Corp. - October 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs t…
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a “clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Find out if you may qualify to recover losses.